Developing and launching a product is a challenge for any innovator, but when it’s a medical product for use on people the journey can be lengthy, complicated and heavily regulated. Professor Anthony Weiss established a company, Elastagen, in order to take his medical innovation successfully to market. He talked with us about the challenges and rewards.
How did the idea of Elastagen begin?
It began when I realised we needed to have a vehicle to commercialise the innovations coming out of my lab. Universities are fine places to generate new ideas and contribute to society in many ways, but they are not necessarily the best place when it comes to commercialisation.
Elastagen is a Pty Ltd company that focuses on the commercialisation and applications of material discoveries from my lab to benefit people. It’s a healthcare focused company. The specific products revolve around the use of a material, ‘tropoelastin’, which is a protein that’s the building block used to make all biological elastic tissues, such as skin, blood vessels, tendons and ligaments.
Naturally occurring elastin is very hard to get hold of. It’s stable because elastin needs to stay intact – although you want your skin and any other flexible structures in your body to be able to move, they have to maintain integrity, so for example those blood vessels can’t fall apart when the blood moves through them – and it’s difficult to access the elastin built into these structures.
So the very first bit of technology coming out of my lab, was to invent the technology to make the individual building blocks for elastin. We found a natural way to make it without having to turn to less ethical sources such as animal or human tissues. We make a precise replica of the natural building blocks. We make this in large amounts. The practical applications are amazing and life-changing.
One example is treating a region of damaged skin. You can reintroduce the building blocks, the tropoelastin, and that can be used to repair the damage. The first product coming through is based on injection. We also have other products in the pipeline that are larger constructs that can be used to treat larger areas of damaged skin, such as burns or scarring.
Further challenges and the regulatory environment
A challenge is bringing in people who want to put funding in and really help establish a company. I’m very grateful for the assistance of Australia Technology Park who’ve been wonderful. There is also a challenge in bringing in the right people, the best team, to make sure you can progress down the commercialisation path.
Underneath all that, you absolutely need robust science. It has to be something that can withstand scrutiny and it has to be original and significant so that it generates substantial intellectual property. With any product intended for use in the treatment of health conditions there has to be a stage involving clinical trials before you can bring it to market. You can’t just invent the technology or the product and bring it out the next day. You do need to conduct clinical trials, you do need to demonstrate that it works well and that it’s a safe material. I like to see this as a partnership with the public; we generate something that benefits the public but the public has also contributed to this process, via funding of my lab. We have a responsibility to give something back to the community.
The regulatory environment sounds like a pain, and it is – but it’s a necessary pain. We want to be sure that what is brought out does indeed help people. Ensuring safety and efficacy of anything we use on people is important. So I’m OK with the regulations.
Advice for young inventors, entrepreneurs and scientists
You need to have the robust science and it has to connect the dots to give the consumer a great end product. I’d encourage young entrepreneurs and inventors to get into commercialisation. Contributing something that meaningfully improves people’s lives is exciting and worthwhile. I’m excited by it and it’s a powerful driver because you can help people.
I say go for it. It’s a worthwhile journey. There will be both small and big bumps along the road but as long as you believe in the outcome and you do things carefully and robustly throughout, what a fantastic journey it will be.
People are critical to success
We talk a lot about the need for robust science, but the people that surround you are just as critical. If you’re a young scientist you need the right mentors. It’s an unknown journey ahead and you want to minimise mistakes and maximise your opportunities, and you want people who can introduce you to other key people.
The things we do best are done with really good people around us. Our company would not have progressed like it has without our wonderful CEO and smart people on the board. The investors have to be the right types of people, people who just ‘get it’. You can start small and build it up. I would always counsel anyone to find the right people to help them.
The need to be truly innovative
In our case we are fortunate that we have really strong dominance in the space. You don’t want anything that provides only a small benefit. It has to make a bigger impact to be commercially viable, and to make the lengthy, difficult journey worthwhile.
If your product or process only offers an incremental benefit, say 3% improvement, then you are vulnerable to the next person that comes along and can offer something with a 5% improvement that knocks yours off the top spot.
Once you start talking about commercialisation and taking something to market you really have to maintain that competitive edge to be economically viable. When you have a good product it’s inevitable that you will have imitators follow. If you are the leader in the field, others will come along; but if you have a hundred-fold lead rather than a five-fold lead, you have a better buffer.
The future of MedTech
I’m quite bullish about it. Australia has a nice history of generating a couple of big companies, for example, the cochlear and sleep apnea products. Australia has a good robust academic research system. I think we have a great future ahead but there are a number of things to be done to secure that future.
One, there has to be continuing and expanding funding in Australia to make things work well. The very foundation of medical technology is expensive. You have to keep on funding the wellsprings from where these discoveries are made, the universities, the CSIRO, the institutes, you have to keep on funding companies as more and more these are involved in discoveries. Not enough of them yet, we still need more.
You have to nurture your base. There needs to be a continuing environment of funding and a regulatory framework that makes it possible for med-tech to continue; Australia already has fine researchers but they need to be nurtured or we’ll lose the bright ones. We do need smarter management that can help drive these discoveries further forward.
Finally, we need to have some really fine examples out there, the newer discoveries, and celebrate the successes so that others will continue to step in. We need to celebrate not just Aussie success but also the people who have tried and failed for the best of reasons and are now doing and redoing new work, who are not giving up.
It’s not a very Aussie thing, to shout about your achievements, but we need to do it; if you are working in that entrepreneurial space, you need to be able to shout to the rooftops that you have a great product that can help change people’s lives.
Give it time and we’ll get better at it. Because we have many wonderful success stories in med-tech to tell, and many more that are still unfolding.
It can be a long journey in med-tech and you need to be passionate about it, because passion not only sustains you, it’s contagious, and it inspires others. I’m still as excited by my career now as I was decades ago when I first started.
I sometimes marvel that the idea I first conceived with scribbles on a whiteboard has had such legs and has moved so far. It has now come to fruition as a life-changing product. I believe that if you have that belief, and that passion, you just have to have a crack at it.
This article was produced in partnership with the Medical Technology Association of Australia and originally appeared on their website.
The Australian Chamber is delighted to announce Bryan Clark, Director of ACCI Trade & International Affairs, has been appointed to the Government’s Deregulation Taskforce, announced...
“New data released today by the ABS confirms that Australians not only have the right to strike but use it, contrary to the exaggerations of...
Australia’s largest and most representative business network, the Australian Chamber of Commerce and Industry, today welcomed...
“Parliament should be congratulated for taking an important first step towards repairing our industrial relations system," Scott Barklamb, the Australian Chamber of Commerce and Industry's...
Australia’s largest and most representative business network, the Australian Chamber of Commerce and Industry, has renewed its call to accelerate action through the Skilling Australians Fund (SAF) to boost falling...
The Federal Government should drop its plans to introduce the Electricity Price Monitoring and Response Legislative Framework Bill 2018 in its current form, Australia’s largest...
Australia’s largest and most representative business network, the Australian Chamber of Commerce and Industry, has warmly welcomed the vocational education and training (VET) announcements made...
“New data released today exposes false claims by big unions about how Australians work,” Australian Chamber CEO, James Pearson, said in response to the latest...
Prime Minister Scott Morrison will tonight address more than 350 members, supporters and guests of Australia’s largest and most representative business network at the Australian...
In response to Opposition Leader Bill Shorten’s speech on Labor energy policy today, Australia’s largest and most representative business network, the Australian Chamber of Commerce...
Australia’s largest and most representative business voice, the Australian Chamber of Commerce and Industry, today called on the ACTU to end its unjustified attack on Australians...
Cuts to Australia’s permanent migration program would be a major concern to business and should be a concern to all Australians, the Australian Chamber of...
The Australian Bureau of Statistics (ABS) reporting of 25,400 new jobs in October – an increase of 7,800 above the number of new jobs created...
The ACTU is sowing confusion by claiming wages are staying low following the latest wage growth data. The facts are the Australian Bureau of Statistics...
"The government's decision to improve access for small businesses to finance is welcome,” James Pearson, Chief Executive of the Australian Chamber of Commerce and Industry...
Australia’s peak body of tourism organisations, Australian Chamber-Tourism, welcomes the growth in value delivered by international visitors to Australia, with total trip spend increasing 5...
The Australian Bureau of Statistics today released inflation figures for the September quarter. Headline inflation was below the RBA’s target of 2-3%, rising 0.4% for...
Australia’s largest and most representative business network, the Australian Chamber of Commerce and Industry, has...
The Australian Chamber of Commerce and Industry's CEO, James Pearson, says today’s announcement by the Federal Government on energy clearly attempts to address some of the...
Big Unions are telling unionists to leave their jobs to attend rallies this week based on deliberate misinformation about how Australians work and the way the Australian industrial relations system...